⌘K

Home/Filings/4/0000014272-21-000028

4//SEC Filing

AHMED NADIM 4

Accession 0000014272-21-000028

CIK 0000014272other

View on SEC.gov Company Profile

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 8:13 PM ET

Size

9.5 KB

Accession

0000014272-21-000028

Insider Transaction Report

Form 4

Period: 2020-12-31

BRISTOL MYERS SQUIBB COBMY

President, Hematology

Transactions

Exercise/Conversion
Restricted Stock Units
2020-12-31−14,946→ 0 total
Exp: 2020-12-31→ Common Stock, $0.10 par value (14,946 underlying)
Tax Payment
Common Stock, $0.10 par value
2020-12-31$62.03/sh−7,660$475,150→ 38,889 total
Exercise/Conversion
Common Stock, $0.10 par value
2020-12-31+14,946→ 46,549 total

Holdings

Common Stock, $0.10 par value
(indirect: By 401(k))
1,966

Footnotes (4)

[F1]In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award.
[F2]Shares withheld for payment of taxes upon vesting of awards.
[F3]Based on recent 401(k) plan statement.
[F4]Each restricted stock unit converts into one share of common stock upon vesting.

Documents

1 file

4
wf-form4_160989560418282.xmlPrimary
FORM 4

Issuer

BRISTOL MYERS SQUIBB CO

CIK 0000014272

Entity typeother

Related Parties

1

filerCIK 0001731193

Filing Metadata

Form type: 4
Filed: Jan 4, 7:00 PM ET
Accepted: Jan 5, 8:13 PM ET
Size: 9.5 KB

View on SEC.gov